| Applicant | Tradename | Generic Name | NDA | Approval Date | Type | Patent Number | Patent Expiration | Patented / Exclusive Use | | Celgene | REVLIMID | lenalidomide | 021880 | Dec 27, 2005 | RX |
7,189,740 | Apr 11, 2023 | REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY | | Celgene | REVLIMID | lenalidomide | 021880 | Jun 29, 2006 | RX |
7,189,740 | Apr 11, 2023 | REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEASET ONE PRIOR THERAPY | | Sanofi Aventis Us | DDAVP | desmopressin acetate | 019955 | Sep 6, 1995 | RX |
7,022,340 | Apr 30, 2023 | | | Bristol Myers Squibb | ZERIT XR | stavudine | 021453 | Dec 31, 2002 | DISCN |
7,135,465 | Aug 18, 2023 | | | Sciele Pharma Inc | ROBINUL | glycopyrrolate | 012827 | Approved Prior to Jan 1, 1982 | RX |
7,091,236 | Aug 20, 2023 | FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER |
|